CMV pp65 mRNA lipid particle vaccine

An off-the-shelf (OTS) lipid particle (LP)-based cancer priming vaccine containing messenger RNA (RNA) encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83), with potential immunostimulatory and antineoplastic activities. Upon administration of CMV pp65 mRNA LP vaccine, the mRNA is taken up, translated and presented by antigen presenting cells (APCs), mainly dendritic cells (DCs). This may result in a specific cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to tumor cell lysis. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.